Aurobindo Expects Interim Phase II/III COVID-19 Vaccine Data By July

Biosimilars Development Progresses

 
• By Vibha Ravi

Aurobindo expects the first data readouts from the Phase II/III clinical trials of its partnered COVID-19 vaccine by July. While making progress in biosimilars development, the Indian company also plans to invest substantially in new API capacity.

Ampule, vials, pharmaceutical factory
Aurobindo Creating Vaccine, API Manufacturing Capacity • Source: Shutterstock

More from R&D

More from Scrip